Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Naval Daver; Aditi Shastri; Tapan Kadia; Alfonso Quintas-Cardama; Elias Jabbour; Marina Konopleva; Susan O'Brien; Sherry Pierce; Lingsha Zhou; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek

doi:10.1016/j.leukres.2013.07.007

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Naval Daver, Aditi Shastri, Tapan Kadia, Alfonso Quintas-Cardama, Elias Jabbour, Marina Konopleva, Susan O'Brien, Sherry Pierce, Lingsha Zhou, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

Original language	English (US)
Pages (from-to)	1440-1444
Number of pages	5
Journal	Leukemia Research
Volume	37
Issue number	11
DOIs	https://doi.org/10.1016/j.leukres.2013.07.007
State	Published - Nov 2013
Externally published	Yes

Keywords

Anemia
Myelofibrosis
Pomalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2013.07.007

Cite this

@article{565d4dcfb6b744c4bb421465993d5a6a,

title = "Modest activity of pomalidomide in patients with myelofibrosis and significant anemia",

abstract = "We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.",

keywords = "Anemia, Myelofibrosis, Pomalidomide",

author = "Naval Daver and Aditi Shastri and Tapan Kadia and Alfonso Quintas-Cardama and Elias Jabbour and Marina Konopleva and Susan O'Brien and Sherry Pierce and Lingsha Zhou and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",

note = "Funding Information: This research is supported in part by the MD Anderson Cancer Center Support Grant CA016672 . ",

year = "2013",

month = nov,

doi = "10.1016/j.leukres.2013.07.007",

language = "English (US)",

volume = "37",

pages = "1440--1444",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "11",

}

TY - JOUR

T1 - Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

AU - Daver, Naval

AU - Shastri, Aditi

AU - Kadia, Tapan

AU - Quintas-Cardama, Alfonso

AU - Jabbour, Elias

AU - Konopleva, Marina

AU - O'Brien, Susan

AU - Pierce, Sherry

AU - Zhou, Lingsha

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

N1 - Funding Information: This research is supported in part by the MD Anderson Cancer Center Support Grant CA016672 .

PY - 2013/11

Y1 - 2013/11

N2 - We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

AB - We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

KW - Anemia

KW - Myelofibrosis

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=84886771903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886771903&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.07.007

DO - 10.1016/j.leukres.2013.07.007

M3 - Article

C2 - 23890523

AN - SCOPUS:84886771903

SN - 0145-2126

VL - 37

SP - 1440

EP - 1444

JO - Leukemia Research

JF - Leukemia Research

IS - 11

ER -

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this